The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect

被引：70

作者：

Pytka, Karolina ^{[1
]}

Dziubina, Anna ^{[1
]}

Mlyniec, Katarzyna ^{[1
]}

Dziedziczak, Agnieszka ^{[1
]}

Zmudzka, Elnieta ^{[1
]}

Furgala, Anna ^{[1
]}

Olczyk, Adrian ^{[2
]}

Sapa, Jacek ^{[1
]}

Filipek, Barbara ^{[1
]}

机构：

[1] Jagiellonian Univ, Coll Med, Fac Pharm, Dept Pharmacodynam, Krakow, Poland

[2] Silesian Tech Univ, Inst Automat Control, Gliwice, Poland

来源：

PHARMACOLOGICAL REPORTS | 2016年 / 68卷 / 02期

关键词：

Animal studies; Glutamatergic receptors; GABA-ergic receptors; Cholinergic receptors; Antidepressant-like effect; FORCED SWIM TEST; CHRONIC MILD STRESS; NICOTINIC ACETYLCHOLINE-RECEPTORS; INCREASES BDNF LEVELS; TAIL SUSPENSION TEST; NMDA RECEPTOR; PREFRONTAL CORTEX; ZINC-DEFICIENCY; MAJOR DEPRESSION; HIPPOCAMPAL NMDA;

D O I：

10.1016/j.pharep.2015.10.006

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Depression is one of the most common mental disorders and social issue worldwide. Although there are many antidepressants available, the effectiveness of the therapy is still a serious issue. Moreover, there are many limitations of currently used antidepressants, including slow onset of action, numerous side effects, or the fact that many patients do not respond adequately to the treatment. Therefore, scientists are searching for new compounds with different mechanisms of action. Numerous data indicate the important role of glutamatergic, GABA-ergic, and cholinergic receptors in the pathomechanism of major depressive disorder. This review presents the role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. (C) 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z.o.o. All rights reserved.

引用

页码：443 / 450

页数：8

共 137 条

[1]

[Anonymous], PHARM REP

[2]

Barnard EA, 1998, PHARMACOL REV, V50, P291

[3]

Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests [J].

Belozertseva, I. V. ;

Kos, T. ;

Popik, P. ;

Danysz, W. ;

Bespalov, A. Y. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (03) :172-179

[4]

Bertrand Daniel, 2005, Dialogues Clin Neurosci, V7, P207

[5]

Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression [J].

Bespalov, Anton Y. ;

van Gaalen, Marcel M. ;

Sukhotina, Irina A. ;

Wicke, Karsten ;

Mezler, Mario ;

Schoemaker, Hans ;

Gross, Gerhard .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 592 (1-3) :96-102

[6]

International Union of Pharmacology.: XXXIII.: Mammalian γ-aminobutyric acidB receptors:: Structure and function [J].

Bowery, NG ;

Bettler, B ;

Froestl, W ;

Gallagher, JP ;

Marshall, F ;

Raiteri, M ;

Bonner, TI ;

Enna, SJ .

PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :247-264

[7]

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain - A quantitative in situ hybridization study [J].

Boyer, PA ;

Skolnick, P ;

Fossom, LH .

JOURNAL OF MOLECULAR NEUROSCIENCE, 1998, 10 (03) :219-233

[8]

GABAergic dysfunction in mood disorders [J].

Brambilla, P ;

Perez, J ;

Barale, F ;

Schettini, G ;

Soares, JC .

MOLECULAR PSYCHIATRY, 2003, 8 (08) :721-737

[9]

Muscarinic receptor agonists and antagonists [J].

Broadley, KJ ;

Kelly, DR .

MOLECULES, 2001, 6 (03) :142-193

[10]

Mechanism of action of A-85380 in an animal model of depression [J].

Buckley, MJ ;

Surowy, C ;

Meyer, M ;

Curzon, P .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (04) :723-730

← 1 2 3 4 5 6 7 8 9 10 →